A Phase 2a trial of ANB020 in patients with severe adult eosinophilic asthma.
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs ANB 020 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 10 Aug 2017 According to an AnaptysBio media release, the company received clearance from the U.K. Medicines & Healthcare products Regulatory Agency to proceed this phase 2a trial in 24 adult patients with severe eosinophilic asthma
- 15 Feb 2017 New trial record
- 13 Feb 2017 According to an AnaptysBio media release, company is seeking for regulatory clearance during the first half of 2017 to initiate this trial and anticipates top-line data during the first half of 2018.